CN1771039A - sgk基因家族用于诊断和治疗白内障和青光眼的用途 - Google Patents

sgk基因家族用于诊断和治疗白内障和青光眼的用途 Download PDF

Info

Publication number
CN1771039A
CN1771039A CNA2004800070348A CN200480007034A CN1771039A CN 1771039 A CN1771039 A CN 1771039A CN A2004800070348 A CNA2004800070348 A CN A2004800070348A CN 200480007034 A CN200480007034 A CN 200480007034A CN 1771039 A CN1771039 A CN 1771039A
Authority
CN
China
Prior art keywords
hsgk1
gene
hsgk3
glaucoma
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800070348A
Other languages
English (en)
Chinese (zh)
Inventor
弗洛里安·朗
安德拉斯·巴斯亚恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1771039A publication Critical patent/CN1771039A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA2004800070348A 2003-02-07 2004-02-05 sgk基因家族用于诊断和治疗白内障和青光眼的用途 Pending CN1771039A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (de) 2003-02-07 2003-02-07 Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10305212.7 2003-02-07

Publications (1)

Publication Number Publication Date
CN1771039A true CN1771039A (zh) 2006-05-10

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800070348A Pending CN1771039A (zh) 2003-02-07 2004-02-05 sgk基因家族用于诊断和治疗白内障和青光眼的用途

Country Status (13)

Country Link
EP (1) EP1663246A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006519189A (cg-RX-API-DMAC7.html)
KR (1) KR20050114214A (cg-RX-API-DMAC7.html)
CN (1) CN1771039A (cg-RX-API-DMAC7.html)
AU (1) AU2004210416A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407300A (cg-RX-API-DMAC7.html)
CA (1) CA2514703A1 (cg-RX-API-DMAC7.html)
DE (1) DE10305212A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008394A (cg-RX-API-DMAC7.html)
PL (1) PL378399A1 (cg-RX-API-DMAC7.html)
RU (1) RU2005127808A (cg-RX-API-DMAC7.html)
WO (1) WO2004069258A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200506280B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119303113A (zh) * 2024-09-03 2025-01-14 河北大学附属医院 Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191326A1 (en) * 2004-03-11 2007-08-16 Florian Lang Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases
US20070203085A1 (en) * 2004-03-11 2007-08-30 Florian Lang Methods For Interfering With Fibrosis
DE102004059781A1 (de) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Verwendung der Serum-/Glucocorticoid regulierten Kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
WO2007037560A1 (ja) * 2005-09-30 2007-04-05 Link Genomics, Inc. Sgk2遺伝子の治療的又は診断的用途
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
WO2008079980A1 (en) * 2006-12-22 2008-07-03 Alcon Research, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
EP2667885B1 (en) * 2011-01-25 2018-08-08 Monell Chemical Senses Center Compositions and methods for providing or modulating sweet taste and methods of screening therefor
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535673D1 (de) * 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
CA2222562A1 (en) * 1995-06-07 1996-12-19 Jeffrey N. Miner Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
AU3991499A (en) * 1998-05-15 1999-12-06 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
WO2000035946A1 (en) * 1998-12-14 2000-06-22 The University Of Dundee Methods
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (de) * 2002-06-04 2003-12-18 Lang Florian sgk und nedd als diagnostische und therapeutische targets

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119303113A (zh) * 2024-09-03 2025-01-14 河北大学附属医院 Nedd4l基因在制备治疗血管内皮细胞增生性相关疾病药物中的应用

Also Published As

Publication number Publication date
CA2514703A1 (en) 2004-08-19
ZA200506280B (en) 2006-05-31
WO2004069258A3 (de) 2005-02-24
KR20050114214A (ko) 2005-12-05
RU2005127808A (ru) 2006-05-27
PL378399A1 (pl) 2006-04-03
WO2004069258A2 (de) 2004-08-19
DE10305212A1 (de) 2004-08-19
AU2004210416A1 (en) 2004-08-19
MXPA05008394A (es) 2005-10-05
BRPI0407300A (pt) 2006-02-07
EP1663246A2 (de) 2006-06-07
JP2006519189A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
CN1604968A (zh) 基于tcf1基因多态性治疗糖尿病和相关病症的方法
CN1313773A (zh) 来自端粒酶的抗原性肽
CN1934256A (zh) 针对滑膜蛋白基因启动子的诱杀核酸
CN1514878A (zh) 在生物样品中检测钙蛋白酶3活性的方法和实施该方法所用的肽
CN1708589A (zh) Cns中crh应答基因
CN1897951A (zh) h-PRUNE的酶抑制剂在过度表达h-PRUNE的肿瘤转移的预防和治疗中的应用
CN1211486C (zh) 编码前神经肽y原突变体,一种信号肽的突变体,的dna分子及其应用
CN1761760A (zh) hsgk1基因中新的多态性在诊断高血压中的用途和sgk基因家族在诊断和治疗长Q/T综合征中的用途
CN1245536A (zh) 新型钙蛋白酶,其制备和用途
HK1089682A (en) Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma
CN1871361A (zh) 使用半乳凝集素-2基因内单碱基多态性进行的炎症性疾病的判定方法
CN1749415A (zh) 硝酸甘油治疗急性心绞痛疗效检测方法和试剂盒
CN1860371A (zh) 用作关节炎和其它炎性疾病的药物靶的ζ蛋白激酶C
CN1515680A (zh) 离子通道抑制剂在治疗心律失常中的应用
CN1516596A (zh) 调节心脏细胞中钙通道活性的方法及其试剂
CN1864743A (zh) 用于治疗胰岛素抗性和以胰岛素抗性为特征的疾病状态的方法
CN1708511A (zh) 对促肾上腺皮质激素释放激素刺激的应答而表达增加的基因
CN1690222A (zh) 耳聋相关基因突变的检测方法
CN1882705A (zh) 遗传多态性用于预测药物诱导肝脏毒性的用途
CN1824776A (zh) 扩张型心肌病诊断和治疗方法及用于该方法的试剂
CN1721549A (zh) 预测中国人2型糖尿病易感性的试剂盒及引物
CN1229386C (zh) 具有抑癌功能的新的人蛋白及其编码序列
CN101033487A (zh) 检测与原发性高血压相关的KLK1基因rs5517多态的方法
CN1958605A (zh) Spg3a基因突变、其编码产物及其应用
CN1303209C (zh) 人胆固醇酯合成酶-1b及其编码序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1089682

Country of ref document: HK

AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1089682

Country of ref document: HK